Title |
Profile of lebrikizumab and its potential in the treatment of asthma
|
---|---|
Published in |
Journal of Asthma and Allergy, August 2015
|
DOI | 10.2147/jaa.s69932 |
Pubmed ID | |
Authors |
Diego Jose Maselli, Holly Keyt, Linda Rogers |
Abstract |
Interleukin (IL)-13 has been associated with multiple inflammatory features of asthma. It affects multiple cellular lines in asthma and is a key mediator in airway hyperreactivity and remodeling. Periostin, an extracellular protein, has been used as a surrogate marker of IL-13 activity and has been linked to airway remodeling by inducing subepithelial fibrosis. Lebrikizumab is a humanized monoclonal antibody that targets IL-13. Studies have demonstrated promising results with lebrikizumab therapy in asthma with regard to pulmonary function and exacerbation rates, especially on those patients with surrogate markers of T helper cell type 2-driven inflammation (ie, elevated immunoglobulin E levels, eosinophil counts, periostin levels). Lebrikizumab appears to be a safe therapy, but there are ongoing studies evaluating its efficacy and safety profile. Other therapies that target IL-13 and the receptor of IL-4/IL-13 have been studied, but future studies are needed to determine their role in the treatment of asthma. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 67% |
Members of the public | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Turkey | 1 | 3% |
Unknown | 38 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 26% |
Student > Ph. D. Student | 5 | 13% |
Student > Bachelor | 4 | 10% |
Other | 4 | 10% |
Professor | 2 | 5% |
Other | 6 | 15% |
Unknown | 8 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 31% |
Agricultural and Biological Sciences | 7 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 13% |
Biochemistry, Genetics and Molecular Biology | 3 | 8% |
Immunology and Microbiology | 3 | 8% |
Other | 2 | 5% |
Unknown | 7 | 18% |